Ken Rhodes

"People around the company are very excited about this," says Kenneth Rhodes, Biogen's vice president of discovery neurobiology."It's potentially a transformational therapy."
...
Other researchers are working on myelin repair, such as a group led by Bruce Trapp at the Cleveland Clinic, says Rhodes, the Biogen vice president.
...
Biogen is developing a genetically engineered antibody against Lingo because that approach should do a better job of binding with the Lingo protein target on the surface of cells, Rhodes says.The first version, however, wasn't quite "optimal," and a newer one is being engineered with better properties, he says.The latest version is made with fully human DNA, instead of partial mouse DNA, because researchers want to be confident that the drug won't spark the immune system to reject it, especially if it needs to be given chronically.The company is planning to ask the FDA for permission to start its first human clinical trials, although he wouldn't say when.

No details are available yet on how the trials will be crafted, but Rhodes made clear that the company's vision is for Lingo to be used in combination with Avonex or Tysabri.

"People around the company are very excited about this," says Kenneth Rhodes, Biogen's vice president of discovery neurobiology."It's potentially a transformational therapy."
...
Other researchers are working on myelin repair, such as a group led by Bruce Trapp at the Cleveland Clinic, says Rhodes, the Biogen vice president.
...
Biogen is developing a genetically engineered antibody against Lingo because that approach should do a better job of binding with the Lingo protein target on the surface of cells, Rhodes says.The first version, however, wasn't quite "optimal," and a newer one is being engineered with better properties, he says.The latest version is made with fully human DNA, instead of partial mouse DNA, because researchers want to be confident that the drug won't spark the immune system to reject it, especially if it needs to be given chronically.The company is planning to ask the FDA for permission to start its first human clinical trials, although he wouldn't say when.

No details are available yet on how the trials will be crafted, but Rhodes made clear that the company's vision is for Lingo to be used in combination with Avonex or Tysabri.

"These exciting results support further research, as the data suggest that neublastin may have the potential to promote sensory neuronal regeneration and functional recovery following injury," said Ken Rhodes, PhD, Vice President, Discovery Neurobiology, Biogen Idec.

and Kenneth J. Rhodes, PhD, Biogen Idec, Inc. (confirmed)

Kenneth J. Rhodes, PhD, Biogen Idec, Inc. (confirmed)